Skip to main content

Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings

June 8, 2016

Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings Sarah E. Rutstein, Joan T. Price, Nora E. Rosenberg, Stuart M. Rennie, Andrea K. Biddle, & William C. Miller Published 2016 May 4 in Journal of Public Health. Cost-effectiveness analysis (CEA) is an increasingly appealing tool for evaluating and comparing health-related interventions … Continued

Citizen science or scientific citizenship?

June 7, 2016

Citizen science or scientific citizenship? Disentangling the uses of public engagement rhetoric in national research initiatives J. Patrick Woolley, Michelle L. McGowan, Harriet J. A. Teare, Victoria Coathup, Jennifer R. Fishman, Richard A. Settersten Jr., Sigrid Sterckx, Jane Kaye & Eric T. Juengst Published 2016 June 4 in BMC Medical Ethics. The language of ‚Äúparticipant-driven … Continued

Oak Ritchie

May 16, 2016

Oak Ritchie, MSIS, has worked in media for over 16 years on projects on major motion pictures, music projects, and documentary film. His research area focuses around web technologies, how messages are transmitted through them, and their influence on social behaviors. He currently serves as Public Communications Specialist for the UNC Center for Bioethics as … Continued

Reframing Conscientious Care: Q&A with Mara Buchbinder

May 16, 2016

Mara Buchbinder, Ph.D. Published May 13th on The Hastings Center Bioethics Forum. “Much of the conversation about conscience in health care has focused on the ethics of physician refusal to perform procedures that they object to. However, this framework seems insufficient for thinking about contemporary abortion provision, where new legislation is routinely passed to restrict … Continued

Professional ‘Guinea Pigs’ Can Make A Living Testing Drugs

May 11, 2016

Jill A. Fisher, Ph.D. Published May 8th on NPR. “I am very concerned about the fact that we’re using a segment of our population who might not ever be able to afford the drugs that they’re part of testing, and not compensating them perhaps to the degree that we really should” Read more